Teva Leapfrogs Taro With Authorized Generic Epiduo Forte Launch
Israeli Firm Celebrates First-To-Market Launch
Executive Summary
Teva has added another major dermatology brand to its armory, with the launch of an authorized generic version of Galderma’s Epiduo Forte Gel.
You may also be interested in...
Asia Deal Watch: Huadong Licenses Two Cancer ADCs From Heidelberg Pharma
German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.
Q4 May Signal If Winlevi Can Give Wings To Sun’s US Specialty Sales
Sun-Cassiopea’s first-in-class topical androgen receptor inhibitor, Winlevi, appears off to an encouraging start in the US, generating prescriptions from 80% of targeted physicians. Can it hold out in the competitive acne therapy segment and add sheen to Sun’s specialty portfolio?
Teva Capitalizes On Patent Expiry To Launch First Perforomist Rival
Teva has added to its vast portfolio in the US by introducing the first generic version of Viatris’ Perforomist for chronic obstructive pulmonary disease, as well as a generic of Soolantra to treat rosacea.